Consonance Capital Management LP Spectrum Pharmaceuticals Inc Transaction History

Consonance Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$9.08 - $11.84 $27 Million - $35.2 Million	-2,969,027 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$6.39 - $16.99 $18.3 Million - $48.6 Million	-2,860,851 Reduced 49.07%	2,969,027 $26 Million
Q3 2018 Nov 14, 2018	SELL	$16.52 - $24.82 $18.7 Million - $28.1 Million	-1,133,878 Reduced 16.28%	5,829,878 $97.9 Million
Q2 2018 Aug 14, 2018	BUY	$14.31 - $21.75 $10.9 Million - $16.5 Million	760,400 Added 12.26%	6,963,756 $146 Million
Q1 2018 May 15, 2018	SELL	$16.09 - $23.07 $19 Million - $27.2 Million	-1,180,110 Reduced 15.98%	6,203,356 $99.8 Million
Q4 2017 Feb 14, 2018	SELL	$13.36 - $20.73 $17.7 Million - $27.5 Million	-1,325,665 Reduced 15.22%	7,383,466 $140 Million
Q3 2017 Nov 14, 2017	BUY	$8.75 - $14.07 $76.2 Million - $123 Million	8,709,131	8,709,131 $123 Million

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Consonance Capital Management LP with notifications on news.